The study found that patients with lower BMIs were more likely to respond effectively to INH medication and show improved clinical response, possibly due to a correlation between lower BMI and better prognosis for TB treatment with INH, and lower plasma ALT and AST levels. The gene discussed is GPT; the disease is tuberculosis.